Results 41 to 50 of about 501,228 (292)

EUS-FNA versus EUS-FNB in Pancreatic Solid Lesions ≤ 15 mm

Diagnostics
A small tumor size may impact the diagnostic performance of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for diagnosing solid pancreatic lesions (SPLs).
Maria Cristina Conti Bellocchi, Micol Bernuzzi, Alessandro Brillo, Laura Bernardoni, Antonio Amodio, Nicolò De Pretis, Luca Frulloni, Armando Gabbrielli, Stefano Francesco Crinò   +8 more
doaj   +1 more source

Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer

BMC Gastroenterology, 2018
Background Patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC) are frequently found to be unresectable on exploration due to small distant metastasis.
Xinchun Liu, Yue Fu, Qiuyang Chen, Junli Wu, Wentao Gao, Kuirong Jiang, Yi Miao, Jishu Wei   +7 more
doaj   +1 more source

Safe perioperative management of major hepatectomy in a patient with portal hypertension after elimination of hepatitis C: a case report

Surgical Case Reports, 2022
Background The administration of direct-acting antiviral agents in patients with liver cirrhosis and hepatitis C has been shown to improve liver function and long-term prognosis after sustained virological response (SVR) is achieved. However, in patients
Ryoga Hamura, Shinji Onda, Yoshihiro Shirai, Jungo Yasuda, Koichiro Haruki, Kenei Furukawa, Taro Sakamoto, Takeshi Gocho, Toru Ikegami   +8 more
doaj   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study

BMC Cancer
Objective Pancreatectomy remains associated with a high incidence of complications. In certain cases, patients with pancreatic ductal adenocarcinoma (PDAC) face challenges in removing intraperitoneal drainage after surgery, leading to potential delays in
Dong Xu, Nan Lv, Qianqian Wang, Yang Wu, Kai Zhang, Yi Miao, Jishu Wei, Min Tu, Kuirong Jiang   +8 more
doaj   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting

BMC Cancer
Background This study aimed to compare the benefits and identify the best second-line treatment regimen for gemcitabine-refractory unresectable pancreatic cancers.
Qianqian Wang, Nan Lv, Dong Xu, Yang Wu, Junli Wu, Wentao Gao, Jishu Wei, Bin Xiao, Min Tu, Kuirong Jiang   +9 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Trends in 5-year cancer survival disparities by race and ethnicity in the US between 2002–2006 and 2015–2019

Scientific Reports
Racial and ethnic disparities persist in cancer survival rates across the United States, despite overall improvements. This comprehensive analysis examines trends in 5-year relative survival rates from 2002–2006 to 2015–2019 for major cancer types ...
Chongfa Chen, Lingdi Yin, Chunhui Lu, Guangfu Wang, Zhenyu Li, Feihu Sun, Huijuan Wang, Chenchen Li, Shangnan Dai, Nan Lv, Jishu Wei, Zipeng Lu, Feng Guo, Min Tu, Bin Xiao, Chunhua Xi, Kai Zhang, Qiang Li, Junli Wu, Wentao Gao, Xu Feng, Kuirong Jiang, Yi Miao   +22 more
doaj   +1 more source